Karamikheirabad, M.; Zhang, J.; Ahn, A.-R.; Park, H.S.; Park, S.-H.; Moon, Y.J.; Kim, K.M.; Jang, K.Y.
IL-13Rα2 Is Involved in Resistance to Doxorubicin and Survival of Osteosarcoma Patients. Pharmaceuticals 2024, 17, 1526.
https://doi.org/10.3390/ph17111526
AMA Style
Karamikheirabad M, Zhang J, Ahn A-R, Park HS, Park S-H, Moon YJ, Kim KM, Jang KY.
IL-13Rα2 Is Involved in Resistance to Doxorubicin and Survival of Osteosarcoma Patients. Pharmaceuticals. 2024; 17(11):1526.
https://doi.org/10.3390/ph17111526
Chicago/Turabian Style
Karamikheirabad, Maryam, Junyue Zhang, Ae-Ri Ahn, Ho Sung Park, See-Hyoung Park, Young Jae Moon, Kyoung Min Kim, and Kyu Yun Jang.
2024. "IL-13Rα2 Is Involved in Resistance to Doxorubicin and Survival of Osteosarcoma Patients" Pharmaceuticals 17, no. 11: 1526.
https://doi.org/10.3390/ph17111526
APA Style
Karamikheirabad, M., Zhang, J., Ahn, A.-R., Park, H. S., Park, S.-H., Moon, Y. J., Kim, K. M., & Jang, K. Y.
(2024). IL-13Rα2 Is Involved in Resistance to Doxorubicin and Survival of Osteosarcoma Patients. Pharmaceuticals, 17(11), 1526.
https://doi.org/10.3390/ph17111526
